Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer | Zendy

Fabian Coscia | Zendy; Ernst Lengyel | Zendy; Jaikumar Duraiswamy | Zendy; Bradley Ashcroft | Zendy; Michal BassaniSternberg | Zendy; Michael Wierer | Zendy; Alyssa E. Johnson | Zendy; Kristen Wroblewski | Zendy; Anthony Montag | Zendy; S. Diane Yamada | Zendy; Blanca LópezMéndez | Zendy; Jakob Nilsson | Zendy; Andreas Mund | Zendy; Matthias Mann | Zendy; Marion Curtis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer

Author(s) -

Fabian Coscia,

Ernst Lengyel,

Jaikumar Duraiswamy,

Bradley Ashcroft,

Michal BassaniSternberg,

Michael Wierer,

Alyssa E. Johnson,

Kristen Wroblewski,

Anthony Montag,

S. Diane Yamada,

Blanca LópezMéndez,

Jakob Nilsson,

Andreas Mund,

Matthias Mann,

Marion Curtis

Publication year - 2018

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2018.08.065

Subject(s) - biology , ovarian cancer , proteomics , cancer research , immunotherapy , cancer , proteome , cytotoxic t cell , cancer cell , immunology , bioinformatics , immune system , in vitro , genetics , gene

Most high-grade serous ovarian cancer (HGSOC) patients develop resistance to platinum-based chemotherapy and recur, but 15% remain disease free over a decade. To discover drivers of long-term survival, we quantitatively analyzed the proteomes of platinum-resistant and -sensitive HGSOC patients from minute amounts of formalin-fixed, paraffin-embedded tumors. This revealed cancer/testis antigen 45 (CT45) as an independent prognostic factor associated with a doubling of disease-free survival in advanced-stage HGSOC. Phospho- and interaction proteomics tied CT45 to DNA damage pathways through direct interaction with the PP4 phosphatase complex. In vitro, CT45 regulated PP4 activity, and its high expression led to increased DNA damage and platinum sensitivity. CT45-derived HLA class I peptides, identified by immunopeptidomics, activate patient-derived cytotoxic T cells and promote tumor cell killing. This study highlights the power of clinical cancer proteomics to identify targets for chemo- and immunotherapy and illuminate their biological roles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research